Abstract
In the past few years, intestinal microbiota has emerged as a novel target for the treatment of gut-brain axis alterations. These include functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), which can be comorbid with stress-related psychiatric conditions. Thus, modulation of the microbiota (e.g. with the use of probiotics) could be proposed as a novel strategy not only for the treatment of IBS but also as an adjuvant for psychiatric treatment of anxiety and depression.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Anxiety / drug therapy
-
Anxiety / microbiology
-
Central Nervous System / microbiology
-
Central Nervous System / physiopathology
-
Depression / drug therapy
-
Depression / microbiology
-
Gastrointestinal Diseases / drug therapy
-
Gastrointestinal Diseases / microbiology*
-
Gastrointestinal Diseases / physiopathology
-
Gastrointestinal Tract / microbiology*
-
Gastrointestinal Tract / physiopathology
-
Humans
-
Irritable Bowel Syndrome / drug therapy
-
Irritable Bowel Syndrome / microbiology*
-
Irritable Bowel Syndrome / physiopathology
-
Probiotics / therapeutic use
-
Stress, Psychological / drug therapy
-
Stress, Psychological / microbiology